Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder.

Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB.

Psychopharmacology (Berl). 2004 Aug;174(4):525-9. Epub 2003 Sep 4.

PMID:
12955294
2.

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.

Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF.

Arch Gen Psychiatry. 2004 Nov;61(11):1163-9.

PMID:
15520364
3.

Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism.

Umene-Nakano W, Yoshimura R, Ueda N, Suzuki A, Ikenouchi-Sugita A, Hori H, Otani K, Nakamura J.

J Psychopharmacol. 2010 Dec;24(12):1764-71. doi: 10.1177/0269881109106899. Epub 2009 Oct 13.

PMID:
19825907
4.
5.

Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder.

Mushtaq D, Ali A, Margoob MA, Murtaza I, Andrade C.

J Affect Disord. 2012 Feb;136(3):955-62. doi: 10.1016/j.jad.2011.08.033. Epub 2011 Sep 29.

PMID:
21962566
6.

An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.

Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K; Sertraline Elderly Depression Study Group.

Am J Psychiatry. 2003 Jul;160(7):1277-85.

PMID:
12832242
7.

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, Fukuda K, Azuma J, Kinoshita T.

Int Clin Psychopharmacol. 2005 May;20(3):151-6.

PMID:
15812265
8.

Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment.

Putzhammer A, Schoeler A, Rohrmeier T, Sand P, Hajak G, Eichhammer P.

Psychopharmacology (Berl). 2005 Mar;178(2-3):303-8. Epub 2004 Aug 18.

PMID:
15322730
9.

Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.

Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK.

JAMA. 2006 Oct 4;296(13):1609-18.

PMID:
17018806
10.
11.

Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities.

Ng CH, Easteal S, Tan S, Schweitzer I, Ho BK, Aziz S.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jul;30(5):953-7. Epub 2006 Apr 3.

PMID:
16580768
12.

Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression.

Taylor WD, Steffens DC, Payne ME, MacFall JR, Marchuk DA, Svenson IK, Krishnan KR.

Arch Gen Psychiatry. 2005 May;62(5):537-44.

PMID:
15867107
13.
14.

Prediction and structural equation model of sertraline treatment response in Japanese patients with major depressive disorder.

Nishioka G, Yashima H, Kiuchi Y, Nakamura S, Oyamada H, Ishii M, Kudo I.

Hum Psychopharmacol. 2013 Nov;28(6):576-85. doi: 10.1002/hup.2347. Epub 2013 Oct 7.

PMID:
24519691
15.

Serotonin transporter genotype and function in relation to antidepressant response in Koreans.

Myung W, Lim SW, Kim S, Kim H, Chung JW, Seo MY, Kim JW, Carroll BJ, Kim DK.

Psychopharmacology (Berl). 2013 Jan;225(2):283-90. doi: 10.1007/s00213-012-2813-y. Epub 2012 Aug 12.

PMID:
22885912
16.

Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression.

Neumeister A, Konstantinidis A, Stastny J, Schwarz MJ, Vitouch O, Willeit M, Praschak-Rieder N, Zach J, de Zwaan M, Bondy B, Ackenheil M, Kasper S.

Arch Gen Psychiatry. 2002 Jul;59(7):613-20.

PMID:
12090814
17.

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.

Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R.

Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):36-40.

PMID:
15274037
18.

Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system.

Brunoni AR, Kemp AH, Shiozawa P, Cordeiro Q, Valiengo LC, Goulart AC, Coprerski B, Lotufo PA, Brunoni D, Perez AB, Fregni F, Benseñor IM.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1530-40. doi: 10.1016/j.euroneuro.2013.03.009. Epub 2013 Apr 21.

PMID:
23615118
19.

A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.

Sechter D, Troy S, Paternetti S, Boyer P.

Eur Psychiatry. 1999 Mar;14(1):41-8.

PMID:
10572324
20.

Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression.

Ravindran AV, Guelfi JD, Lane RM, Cassano GB.

J Clin Psychiatry. 2000 Nov;61(11):821-7.

PMID:
11105734

Supplemental Content

Support Center